SCHEMBL7203231

SCHEMBL7203231

CC(C)(C)NS(=O)(=O)c1ccc(CSCc2cccc(CBr)c2)cc1

nearest known ligand 0.44

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.44
NPC1 O15118 2/20 0.44
RAB9A P51151 2/20 0.44
SMN1; SMN2 Q16637 2/20 0.44
MEN1 O00255 2/20 0.44
KMT2A Q03164 2/20 0.44
LMNA P02545 2/20 0.44
KDM4E B2RXH2 1/20 0.44
HPGD P15428 1/20 0.44
CYP19A1 P11511 7/20 0.42
TNF P01375 1/20 0.42
NOD1 Q9Y239 1/20 0.42
PARG Q86W56 1/20 0.41
ALDH1A1 P00352 6/20 0.40
CA2 P00918 1/20 0.40
GAA P10253 1/20 0.39
TSHR P16473 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1458716 0.80 ALDH1A1 (0.54) MAPTNPC1RAB9ASMN1; SMN2MEN1
SCHEMBL28022953 0.70 MAPT (0.59) MAPTNPC1RAB9ASMN1; SMN2MEN1
SCHEMBL12482759 0.69 ALDH1A1 (0.56) MAPTNPC1RAB9ASMN1; SMN2MEN1
SCHEMBL29405486 0.69 EDNRB (0.41) MAPTNPC1RAB9ASMN1; SMN2MEN1
SCHEMBL22409170 0.69 EDNRB (0.41) MAPTNPC1RAB9ASMN1; SMN2MEN1
SCHEMBL7596576 0.68 LMNA (0.38) MAPTNPC1RAB9ASMN1; SMN2MEN1
SCHEMBL1795036 0.68 USP30 (0.39) MAPTNPC1RAB9ASMN1; SMN2MEN1
SCHEMBL7200197 0.68 ALDH1A1 (0.54) MAPTNPC1RAB9ASMN1; SMN2MEN1
SCHEMBL19287437 0.67 ALDH1A1 (0.50) MAPTNPC1RAB9ASMN1; SMN2MEN1
SCHEMBL8885194 0.67 PARG (0.52) MAPTSMN1; SMN2KMT2ALMNAKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1268494-A1 SULFUR SUBSTITUTED ARYLDIFLUOROMETHYLPHOSPHONIC ACIDS AS PTP-1B INHIBITORS Merck Frosst Canada & Co. (CA) 2003-01-02 EP disclosed
US-6498151-B2 PROTEIN TYROSINE PHOSPHATASES INHIBITORS, ESPECIALLY AS ANTIDIABETIC AGENTS MERCK FROSST CANADA & CO. (CA) 2002-12-24 US disclosed
US-20020091104-A1 Aryldifluoromethylphosphonic acids with sulfur-containing substituents as PTP-1B inhibitors MERCK FROSST CANADA LTD. (CA) 2002-07-11 US disclosed
WO-2001070753-A1 SULFUR SUBSTITUTED ARYLDIFLUOROMETHYLPHOSPHONIC ACIDS AS PTP-1B INHIBITORS MERCK FROSST CANADA & CO. (CA) 2001-09-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020091104-A1 Aryldifluoromethylphosphonic acids with sulfur-containing substituents as PTP-1B inhibitors PTPRF, PTPRS, PTPRO MAPT 4057/4885NPC1 2966/4885RAB9A 911/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.